ClinicalTrials.gg
Not yet recruitingNCT07817394Updated Sep 14, 2026

Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the Treatment of Psoriasis

An interventional study of Doublebase Once in Psoriasis, sponsored by Dermal Laboratories Ltd. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Dermal Laboratories Ltd · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Sex
All
01

Study summary

This PMCF study is to obtain patient feedback using online questionnaires. There will be no involvement from healthcare professionals (HCPs) or investigator sites. Up to 100 Patients are being recruited by My Health Focus through their website. The study is performed throughout the UK except Northern Ireland with no sites involved in this study. Patients apply directly to participate in the study and the testing and questionnaire responses are completed at home.

Read the detailed description

The study is to be performed in liaison with My Health Focus who have been set up to help support, educate and promote research for psoriasis patients. The intention is to utilise their website and patient database to recruit to this study under the management of My Health Focus. This will allow psoriasis patients to access this treatment free of charge and for the Sponsor to obtain key information about how psoriasis patients use Doublebase Once.

Psoriasis patients registered on the My Health Focus database will be advised about the study by adverts on the My Health Focus website or social medial posts and direct email via My Health Focus mailing list. This will briefly summarise the study, the rationale for performing it, and a description of what participation will involve. Any patients interested in taking part will then be asked to register interest by completing a short questionnaire that will be used as a pre-screen tool to exclude any patients who are ineligible for the study.

Patients will then be provided with the Patient Information Sheet (PIS) to read and then complete a consent questionnaire, confirming their agreement to participate in the study. Once consent and assent (where applicable) have been obtained, patients will then complete a screening questionnaire and provide details to fulfil their supplies. My Health Focus and the Sponsor will require access to personal information such as email addresses (for sending the questionnaires and safety monitoring) and home addresses (for sending the packs of Doublebase Once), but these details will be used solely for the purpose of the study.

If all screening questions are completed and the patient is eligible in accordance with the inclusion and exclusion criteria, the patient will then be sent two pump pack of Doublebase Once 500g.

On receipt of their pack(s) of Doublebase Once (Day 0), the patients will be asked to read through all the information provided and to complete an online questionnaire and, if they agreed at consent, they will be asked to photograph one area of their psoriasis that will be treated with the product and upload to the database alongside their questionnaire. Guidance on taking the photos will be provided in the questionnaire with regards to lighting, location, distance, angle of taking photographs, and background. This questionnaire and image(s) will form the baseline 'before using Doublebase Once' and there will be some questions to be completed immediately after first use of the product.

Patients will then be asked to use Doublebase Once, as per the package leaflet for approximately 4 weeks, once daily (unless they need to use it more often) and on their affected psoriasis areas, instead of their usual leave-on emollient. Patients will also be asked to use Doublebase Once instead of their usual wash product. If patients do not want to use Doublebase Once instead of their usual wash products, they will be asked to continue to use their usual products.

While using the product, the patients will be sent further questionnaires to complete on Day 8 and 29 and if they consented to do so, to send further photographs of the same area taken at Day 0.

At the end of the study as part of the final questionnaire, patients will be asked to provide a short review about Doublebase Once and give the product a 'star rating' out of 5 (5 being excellent and 1 being poor).

02

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • PMCF Survey
03

In context

Psoriasis

2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.

This study's planned enrollment of 100 is above the median of 75 across 1,565 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Dermal Laboratories Ltd is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with psoriasis of any severity previously diagnosed by a Healthcare Professional (HCP).
  • Patients normally managing their skin condition by regular and ongoing use of leave-on emollient(s).
  • Patients willing to incorporate Doublebase Once into their normal skin condition management routine for approximately 1 month as their only emollient and instead of their usual emollient

Exclusion criteria

Exclusion Criteria:

  • Does not regularly use an emollient
  • Known history of intolerance or skin sensitivity to any of the ingredients of Doublebase Once (as identified on the Patient Information Sheet and product labelling), or similar products used.
  • Currently participating in a study involving an medicinal product/medical device or having participated in the previous 30 days.
  • Patients currently residing in Northern Ireland (this is due to the different approval process)
  • Patients (or their parents/legal guardians, in the case of infants, very young children or adolescent adults) who may have difficulties completing the feedback questionnaires, which will be written in English only.
  • Employees of My Health Focus or the Sponsor (Dermal or the Diomed group companies), or any immediate family member (partner, offspring, parents, siblings or sibling's offspring) of such employees
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Main Group

    Doublebase Once

    Device: Doublebase Once

Interventions

  • DeviceDoublebase Once

    Once Daily Emollient

06

What researchers measure

Primary outcomes

  1. Emollient performance

    Patient reported questionnaire responses on skin condition and product use. Scoring of 0 - 10 to specific skin condition and product parameters (0=Strongly agree - 10 strongly disagree)

    Time frame: 4 weeks use

Other outcomes

  1. Adverse Device effects and Device deficiencies

    Reported related adverse device effects and Device deficiencies

    Time frame: weeks 1 - 4

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Patient Reported Outcomes

Supporting information: Study protocol, Statistical analysis plan

Time frame: Dec 2026

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07817394
Lead sponsor
Dermal Laboratories Ltd
Responsible party
Sponsor
First posted
Sep 14, 2026
Start date
Sep 21, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Sep 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion